PDF(Pubmed)
Abstract：
UNASSIGNED: Although numerous studies have reported the association between tertiary lymphoid structures (TLSs) and clinical outcomes in cancer patients treated with immune checkpoint inhibitors (ICIs), there remains a lack of a newer and more comprehensive meta-analysis. The main objective of this study is to explore prognostic biomarkers in immunotherapy-related patients, through analyzing the associations between tertiary lymphoid structures (TLSs) and clinical outcomes in cancer patients treated with ICIs, so as to investigate their prognostic value in cancer patients treated with ICIs.
UNASSIGNED: A comprehensive search was conducted until February 2024 across PubMed, Embase, Web of Science, and the Cochrane Library databases to identify relevant studies evaluating the association between tertiary lymphoid structures and clinical outcomes in cancer patients treated with ICIs. The clinical outcomes were overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).
UNASSIGNED: Thirteen studies were incorporated in this meta-analysis, among which nine evaluated the prognostic value of TLSs. The results showed the high levels of TLSs predicted a significantly prolonged OS (pooled HR = 0.35, 95% CI: 0.24-0.53, p < 0.001) and PFS (pooled HR = 0.47, 95% CI: 0.31-0.72, p < 0.001), while lower ORR (pooled OR = 3.78, 95% CI: 2.26-6.33, p < 0.001) in cancer patients treated with ICIs.
UNASSIGNED: Our results indicated that high levels of TLSs could predict a favorable prognosis for cancer patients treated with ICIs and have the potential to become a prognostic biomarker of immunotherapy-related patients.
UNASSIGNED: A comprehensive search was conducted until February 2024 across PubMed, Embase, Web of Science, and the Cochrane Library databases to identify relevant studies evaluating the association between tertiary lymphoid structures and clinical outcomes in cancer patients treated with ICIs. The clinical outcomes were overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).
UNASSIGNED: Thirteen studies were incorporated in this meta-analysis, among which nine evaluated the prognostic value of TLSs. The results showed the high levels of TLSs predicted a significantly prolonged OS (pooled HR = 0.35, 95% CI: 0.24-0.53, p < 0.001) and PFS (pooled HR = 0.47, 95% CI: 0.31-0.72, p < 0.001), while lower ORR (pooled OR = 3.78, 95% CI: 2.26-6.33, p < 0.001) in cancer patients treated with ICIs.
UNASSIGNED: Our results indicated that high levels of TLSs could predict a favorable prognosis for cancer patients treated with ICIs and have the potential to become a prognostic biomarker of immunotherapy-related patients.
摘要：
尽管许多研究报道了三级淋巴结构（TLS）与接受免疫检查点抑制剂（ICIs）治疗的癌症患者的临床结果之间的关联，仍然缺乏更新和更全面的荟萃分析。这项研究的主要目的是探索免疫治疗相关患者的预后生物标志物，通过分析三级淋巴结构（TLSs）与ICIs治疗的癌症患者的临床结果之间的关联，从而探讨其在ICIs治疗癌症患者中的预后价值。
■在PubMed进行了全面搜索，直到2024年2月，Embase,WebofScience,和Cochrane图书馆数据库，以确定相关研究，评估使用ICIs治疗的癌症患者三级淋巴结构与临床结局之间的关系。临床结果为总生存期（OS），无进展生存期（PFS），和客观反应率（ORR）。
■本荟萃分析纳入了13项研究，其中9项评估了TLS的预后价值。结果显示高水平的TLS预测显著延长的OS(合并HR=0.35,95%CI:0.24-0.53,p<0.001)和PFS(合并HR=0.47,95%CI:0.31-0.72,p<0.001),而使用ICIs治疗的癌症患者的ORR较低（合并OR=3.78，95％CI：2.26-6.33，p<0.001）。
■我们的结果表明，高水平的TLS可以预测使用ICIs治疗的癌症患者的良好预后，并有可能成为免疫治疗相关患者的预后生物标志物。
■在PubMed进行了全面搜索，直到2024年2月，Embase,WebofScience,和Cochrane图书馆数据库，以确定相关研究，评估使用ICIs治疗的癌症患者三级淋巴结构与临床结局之间的关系。临床结果为总生存期（OS），无进展生存期（PFS），和客观反应率（ORR）。
■本荟萃分析纳入了13项研究，其中9项评估了TLS的预后价值。结果显示高水平的TLS预测显著延长的OS(合并HR=0.35,95%CI:0.24-0.53,p<0.001)和PFS(合并HR=0.47,95%CI:0.31-0.72,p<0.001),而使用ICIs治疗的癌症患者的ORR较低（合并OR=3.78，95％CI：2.26-6.33，p<0.001）。
■我们的结果表明，高水平的TLS可以预测使用ICIs治疗的癌症患者的良好预后，并有可能成为免疫治疗相关患者的预后生物标志物。
